[Development of prodioxin ointment].
There was a purpose to create a composite ointment of proteolytic and antimicrobial activity, the formulation of which would contain the proteolytic enzyme procelan and the antimicrobial preparation with wide spectrum of action dioxidin. During the development of prodioxin ointment by means of biological experiments the optimal concentration of dioxidin was evaluated; it was 1 percent. The optimal dispersity value of dioxidin particles was estimated by dialysis through a semipermeable membrane. The best release of dioxidine from prodioxin ointment occurred, when it was pulverized to particles with diameter 5-10 mm. The method of assay of dioxidin was modified for the ointment. The physicomechanical properties of the prodioxin ointment: flowability, colloidal stability, thermostability and rheological properties were examined. The investigated ointment is non-newtonian in character, e.g. an elastic and plastic system and may be intended for use in dermatological practice. Medicinal enzymic and antimicrobial effects of the prodioxin ointment were compared with the healing effect of Iruksol ointment. The medicinal effect of the prodioxin ointment exceeded that of Iruksol ointment by one day. Judging by the results of the physicochemical analysis a conclusion can be made that the prodioxin ointment is stable for two years at room temperature.
Puodziūniene
Gene
G
Department of Pharmaceutical Chemistry and Pharmacognosy, Kaunas University of Medicine, Mickeviciaus 9, Lithuania.
Vaiciuvenas
Vytautas
V
Janulis
Valdimaras
V
Steponavicius
Juozas
J
D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage; D002626:Chemistry, Pharmaceutical; D003627:Data Interpretation, Statistical; D003879:Dermatologic Agents / Q000008:administration & dosage; D004339:Drug Compounding; D004355:Drug Stability; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008962:Models, Theoretical; D009823:Ointment Bases; D009824:Ointments; D010447:Peptide Hydrolases / Q000008:administration & dosage; D011810:Quinoxalines / Q000008:administration & dosage; D011817:Rabbits; D013492:Suppuration; D013997:Time Factors; D014946:Wound Infection / Q000188:drug therapy
D000891:Anti-Infective Agents, Local; D003879:Dermatologic Agents; D009823:Ointment Bases; D009824:Ointments; D011810:Quinoxalines; C001077:dioxidine; D010447:Peptide Hydrolases